Back to School: How biopharma can reboot drug development. Access exclusive analysis here

TSI Corp. sales and marketing update

A restructured TSIN reported profits of $117,000 (1 cent per share)

Read the full 116 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE